Laboratorios Farmaceuticos Rovi (41L) AI Stock Analysis

Laboratorios Farmaceuticos Rovi

(XETRA:41L)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Debt-free balance sheetA debt-free balance sheet gives ROVI substantial financial flexibility to fund capacity, product development, or acquisitions without depending on refinancing. The sizable equity base also improves resilience during weaker pharmaceutical demand and supports investment through operating cycles.

Negative Factors

Underlying profitability declineThe sharp decline in EBITDA and EBIT excluding the one-off gain shows that reported profit growth overstates underlying operating progress. If this weakness persists, it could constrain reinvestment capacity and reduce the earnings benefit from otherwise strong revenue and CDMO momentum.

Laboratorios Farmaceuticos Rovi (41L) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 3.19B
Dividend Yield: 1.25%
Average Volume (3M): 78
Price to Earnings (P/E): 17.3
Beta (1Y): 0.52
Revenue Growth: 3.21%
EPS Growth: 39.34%
Country: Germany
Employees: 2,470
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

Laboratorios Farmaceuticos Rovi Business Overview & Revenue Model

Company Description

Laboratorios Farmaceuticos Rovi, S.A. is a pharmaceutical company that focuses on researching, developing, manufacturing, and commercializing medicinal products. Its operations span Spain, the European Union, OECD nations, and global markets. The com...

Laboratorios Farmaceuticos Rovi Earnings Call Summary

Earnings Call Date:Jul 22, 2026(Q2-2026)|% Change Since:14.44%|Next Earnings Date:Nov 04, 2026

Earnings Call SentimentNeutral

The call presented a mix of strong operational and financial positives (double‑digit revenue growth, 38% CDMO growth, improved gross margins, strong cash generation, strategic Phoenix acquisition and clinical progress) alongside material caveats: much of the headline profit uplift was driven by a one‑off EUR 62.4 million badwill, underlying EBITDA and EBIT declined year‑on‑year, SG&A and R&D rose sharply, and the heparin franchise still faces year‑on‑year declines despite recent Q2 improvement. Management maintained cautious full‑year guidance and flagged regulatory and contract timing risks. Overall the results show meaningful momentum in CDMO, cash flow and product development, but underlying operational profitability and cost pressures temper the outlook.

Positive Updates

Total Revenue Growth

Total revenue increased 13% year‑on‑year to EUR 357.0 million in H1 2026; operating revenue rose 9% to EUR 344.2 million, driven mainly by CDMO strength.

Negative Updates

Underlying Profitability Weakness Excluding Badwill

EBITDA rose 85% to EUR 121.2 million, but excluding the EUR 62.4 million badwill EBITDA decreased 10% to EUR 58.8 million; EBIT excluding badwill fell 20% to EUR 40.9 million, indicating weaker underlying operating profitability.

Company Guidance

ROVI reiterated its 2026 guidance, continuing to expect operating revenue to increase by a low- to mid‑single‑digit percentage versus 2025; it also narrowed its heparin outlook, now forecasting low‑molecular‑weight heparins to decline by a mid‑single‑digit percentage (improved from a prior high‑single‑digit decline) while bemiparin is expected to grow by a low single‑digit percentage in 2026 after a strong Q2 recovery (H1 bemiparin sales EUR 46.7m, enoxaparin biosimilar EUR 78.6m, total heparin sales EUR 130.1m, ~38% of operating revenue). The company confirmed continued CDMO expansion after CDMO revenue rose 38% to EUR 106.3m in H1 (Phoenix contributed ~EUR 13.8m and the BMS supply agreement provides a baseline ~USD 50m p.a.), expects SG&A (excluding Phoenix) to increase mid‑ to high‑single‑digits, is maintaining its investment plan (H1 CapEx EUR 30.4m), and highlighted ongoing growth drivers such as Okedi (H1 sales EUR 34m, +27% y/y) and ISM clinical progress.

Laboratorios Farmaceuticos Rovi Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

DE:41L against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ES:GRF	68Neutral	EUR 6.52B	16.38	8.43%	0.75%	-0.33%	51.93%
ES:ALM	65Neutral	EUR 2.31B	32.00	4.78%	1.74%	9.67%	174.00%
ES:PHM	65Neutral	EUR 1.20B	20.69	23.64%	1.48%	15.52%	34.76%
ES:FAE	61Neutral	EUR 1.50B	11.10	18.19%	2.65%	31.88%	-20.09%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
ES:RJF	52Neutral	EUR 212.43M	30.46	3.14%	0.75%	-0.42%	4.56%

* General Sector Average

Performance Comparison

DE:41L and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:41L	Laboratorios Farmaceuticos Rovi	62.60	2.40	3.98%
ES:ALM	Almirall SA	10.60	-1.34	-11.24%
ES:FAE	Faes Farma	4.83	0.50	11.59%
ES:GRF	Grifols (0RDU)	10.97	-0.17	-1.53%
ES:RJF	LABORATORIO REIG JOFRE	2.58	-0.29	-10.01%
ES:PHM	Pharma Mar SA	67.50	-4.57	-6.34%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Laboratorios Farmaceuticos Rovi AI Stock Analysis